Oncolytics CBO granted 260,000 options at $1.06
ONCOLYTICS BIOTECH INC Chief Business Officer Andrew Aromando received a grant of 260,000 stock options.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ONCOLYTICS BIOTECH INC Chief Business Officer Andrew Aromando received a grant of 260,000 stock options. These options have an exercise price of $1.06 per share, equal to the closing price of the company’s common stock on the Nasdaq Capital Market on June 1, 2026.
The options cover 260,000 underlying common shares and expire on June 1, 2036. They vest in three equal annual installments, with the first tranche vesting on June 1, 2027, subject to his continued service or employment on each vesting date.
Insider Trade Summary
Grant/Award: 260,000 shares
Grant/Award
1 txn
Insider
Aromando Andrew
Role
Chief Business Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 260,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option — 260,000 contracts (Direct)
Holdings Before and After:
Stock Option, 0 to 260,000 contracts (Direct)
Footnotes (2)
- F1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
- F2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.
Key Figures
Options granted: 260,000 stock options
Exercise price: $1.06 per share
Underlying shares: 260,000 common shares
+3 more
6 metrics
Options granted
260,000 stock options
Grant to Chief Business Officer on June 1, 2026
Exercise price
$1.06 per share
Equal to closing price on Nasdaq Capital Market on June 1, 2026
Underlying shares
260,000 common shares
Shares issuable upon exercise of options
Expiration date
June 1, 2036
Option term end date
Vesting start
June 1, 2027
First of three equal annual vesting dates
Post-grant derivative holdings
260,000 options
Total options held following this grant
Key Terms
Stock Option, exercise price, Nasdaq Capital Market, vests in three equal annual installments, +1 more
5 terms
Stock Option financial
"security_title: "Stock Option" and underlying_security_title: "Common Shares""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Nasdaq Capital Market financial
"the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
vests in three equal annual installments financial
"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027"
expiration date financial
"expiration_date: "2036-06-01T00:00:00.000Z" for the stock option grant"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ONCY Chief Business Officer Andrew Aromando report on this Form 4?
Andrew Aromando reported receiving a grant of 260,000 stock options. These options give him the right to buy common shares at a fixed exercise price, as part of his compensation package, rather than reflecting any open-market stock purchase or sale.
What is the exercise price of Andrew Aromando’s ONCY stock options?
The stock options have an exercise price of $1.06 per share. This price equals the closing price of ONCOLYTICS BIOTECH INC common stock on the Nasdaq Capital Market on June 1, 2026, the date the options were granted.
When do Andrew Aromando’s ONCY stock options vest?
The options vest in three equal annual installments, starting June 1, 2027. Each tranche requires Andrew Aromando’s continued service or employment with ONCOLYTICS BIOTECH INC on the applicable vesting date before those specific options become exercisable.
When do Andrew Aromando’s ONCY stock options expire?
The stock options expire on June 1, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase ONCOLYTICS BIOTECH INC common shares at the $1.06 exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
